Cancer Research and Treatment

Original Articles

General

The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group: Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yun, Byung-Ho Nam, Dae Young Zang; Cancer Res Treat. 2025;57(1):39-46. Published online July 10, 2024; DOI: https://doi.org/10.4143/crt.2024.421

Abstract PDF PubReader ePub: Purpose
The Korean Cancer Study Group (KCSG) is a nationwide cancer clinical trial group dedicated to advancing investigator-initiated trials (IITs) by conducting and supporting clinical trials. This study aims to review IITs conducted by KCSG and quantitatively evaluate the survival and financial benefits of IITs for patients.
Materials and Methods
We reviewed IITs conducted by KCSG from 1998 to 2023, analyzing progression-free survival (PFS) and overall survival (OS) gains for participants. PFS and OS benefits were calculated as the difference in median survival times between the intervention and control groups, multiplied by the number of patients in the intervention group. Financial benefits were assessed based on the cost of investigational products provided.
Results
From 1998 to 2023, KCSG conducted 310 IITs, with 133 completed and published. Of these, 21 were included in the survival analysis. The analysis revealed that 1,951 patients in the intervention groups gained a total of 2,558.4 months (213.2 years) of PFS and 2,501.6 months (208.5 years) of OS, with median gains of 1.31 months in PFS and 1.58 months in OS per patient. When analyzing only statistically significant results, PFS and OS gain per patients was 1.69 months and 3.02 months, respectively. Investigational drug cost analysis from six available IITs indicated that investigational products provided to 252 patients were valued at 10,400,077,294 won (approximately 8,046,481 US dollars), averaging about 41,270,148 won (approximately 31,930 US dollars) per patient.
Conclusion
Our findings, based on analysis of published research, suggest that IITs conducted by KCSG led to survival benefits for participants and, in some studies, may have provided financial benefits by providing investment drugs.

971 View
79 Download

Gastrointestinal cancer

A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10): Keun-Wook Lee, Dae Young Zang, Min-Hee Ryu, Hye Sook Han, Ki Hyang Kim, Mi-Jung Kim, Sung Ae Koh, Sung Sook Lee, Dong-Hoe Koo, Yoon Ho Ko, Byeong Seok Sohn, Jin Won Kim, Jin Hyun Park, Byung-Ho Nam, In Sil Choi; Cancer Res Treat. 2023;55(4):1250-1260. Published online May 25, 2023; DOI: https://doi.org/10.4143/crt.2023.333

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study evaluated whether combination therapy is more effective than monotherapy in elderly patients with metastatic or recurrent gastric cancer (MRGC) as first-line chemotherapy.
Materials and Methods
Elderly (≥ 70 years) chemo-naïve patients with MRGC were allocated to receive either combination therapy (group A: 5-fluorouracil [5-FU]/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, or S-1/cisplatin) or monotherapy (group B: 5-FU, capecitabine, or S-1). In group A, starting doses were 80% of standard doses, and they could be escalated to 100% at the discretion of the investigator. Primary endpoint was to confirm superior overall survival (OS) of combination therapy vs. monotherapy.
Results
After 111 of the planned 238 patients were randomized, enrollment was terminated due to poor accrual. In the full-analysis population (group A [n=53] and group B [n=51]), median OS of combination therapy vs. monotherapy was 11.5 vs. 7.5 months (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.56 to 1.30; p=0.231). Median progression-free survival (PFS) was 5.6 vs. 3.7 months (HR, 0.53; 95% CI, 0.34 to 0.83; p=0.005). In subgroup analyses, patients aged 70-74 years tended to have superior OS with combination therapy (15.9 vs. 7.2 months, p=0.056). Treatment-related adverse events (TRAEs) occurred more frequently in group A vs. group B. However, among severe TRAEs (≥ grade 3), there were no TRAEs with a frequency difference of > 5%.
Conclusion
Combination therapy was associated with numerically improved OS, although statistically insignificant, and a significant PFS benefit compared with monotherapy. Although combination therapy showed more frequent TRAEs, there was no difference in the frequency of severe TRAEs.

Citations

Citations to this article as recorded by

A prognostic nomogram to predict the cancer-specific survival of patients with initially diagnosed metastatic gastric cancer: a validation study in a Chinese cohort
Ziming Zhao, Erxun Dai, Bao Jin, Ping Deng, Zulihaer Salehebieke, Bin Han, Rongfan Wu, Zhaowu Yu, Jun Ren
Clinical and Translational Oncology.2024;[Epub] CrossRef

3,610 View
296 Download
1 Web of Science
1 Crossref

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma: Sun Min Lim, Sang Hee Cho, In Gyu Hwang, Jae Woo Choi, Hyun Chang, Myung-Ju Ahn, Keon Uk Park, Ji-Won Kim, Yoon Ho Ko, Hee Kyung Ahn, Byoung Chul Cho, Byung-Ho Nam, Sang Hoon Chun, Ji Hyung Hong, Jung Hye Kwon, Jong Gwon Choi, Eun Joo Kang, Tak Yun, Keun-Wook Lee, Joo-Hang Kim, Jin Soo Kim, Hyun Woo Lee, Min Kyoung Kim, Dongmin Jung, Ji Eun Kim, Bhumsuk Keam, Hwan Jung Yun, Sangwoo Kim, Hye Ryun Kim; Cancer Res Treat. 2019;51(1):300-312. Published online May 9, 2018; DOI: https://doi.org/10.4143/crt.2018.012

Abstract PDF Supplementary Material PubReader ePub

Purpose
Head and neck squamous cell carcinoma (HNSCC) is a deadly disease in which precision medicine needs to be incorporated. We aimed to implement next-generation sequencing (NGS) in determining actionable targets to guide appropriate molecular targeted therapy in HNSCC patients.
Materials and Methods
Ninety-three tumors and matched blood samples underwent targeted sequencing of 244 genes using the Illumina HiSeq 2500 platform with an average depth of coverage of greater than 1,000×. Clinicopathological data from patients were obtained from 17 centers in Korea, and were analyzed in correlation with NGS data.
Results
Ninety-two of the 93 tumors were amenable to data analysis. TP53 was the most common mutation, occurring in 47 (51%) patients, followed by CDKN2A (n=23, 25%), CCND1 (n=22, 24%), and PIK3CA (n=19, 21%). The total mutational burden was similar between human papillomavirus (HPV)–negative vs. positive tumors, although TP53, CDKN2A and CCND1 gene alterations occurred more frequently in HPV-negative tumors. HPV-positive tumors were significantly associated with immune signature-related genes compared to HPV-negative tumors. Mutations of NOTCH1 (p=0.027), CDKN2A (p < 0.001), and TP53 (p=0.038) were significantly associated with poorer overall survival. FAT1 mutations were highly enriched in cisplatin responders, and potentially targetable alterations such as PIK3CA E545K and CDKN2A R58X were noted in 14 patients (15%).
Conclusion
We found several targetable genetic alterations, and our findings suggest that implementation of precision medicine in HNSCC is feasible. The predictive value of each targetable alteration should be assessed in a future umbrella trial using matched molecular targeted agents.

Citations

Citations to this article as recorded by

Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial
Bhumsuk Keam, Min Hee Hong, Seong Hoon Shin, Seong Gu Heo, Ji Eun Kim, Hee Kyung Ahn, Yun-Gyoo Lee, Keon-Uk Park, Tak Yun, Keun-Wook Lee, Sung-Bae Kim, Sang-Cheol Lee, Min Kyoung Kim, Sang Hee Cho, So Yeon Oh, Sang-Gon Park, Shinwon Hwang, Byung-Ho Nam, S
Journal of Clinical Oncology.2024; 42(5): 507. CrossRef
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial
Kyoo Hyun Kim, Sun Min Lim, Hee Kyung Ahn, Yun-Gyoo Lee, Keun-Wook Lee, Myung-Ju Ahn, Bhumsuk Keam, Hye Ryun Kim, Hyun Woo Lee, Ho Jung An, Jin-Soo Kim
Cancer Research and Treatment.2024; 56(1): 37. CrossRef
Extracellular vesicles as tools and targets in therapy for diseases
Mudasir A. Kumar, Sadaf K. Baba, Hana Q. Sadida, Sara Al. Marzooqi, Jayakumar Jerobin, Faisal H. Altemani, Naseh Algehainy, Mohammad A. Alanazi, Abdul-Badi Abou-Samra, Rakesh Kumar, Ammira S. Al-Shabeeb Akil, Muzafar A. Macha, Rashid Mir, Ajaz A. Bhat
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, Eun Joo Kang, Hee Kyung Ahn, Yun-Gyoo Lee, Der Sheng Sun, Jung Hye Kwon, Sang-Cheol Lee, Hyun Woo Lee, Min Kyoung Kim, Bhumsuk Keam, Keon-Uk Park, Seong-Hoon Shin, Hwan Jung Yun
Oral Oncology.2024; 151: 106739. CrossRef
Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature
Lei Liu, Qiang Liu
Scientific Reports.2024;[Epub] CrossRef
The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer
Antea Krsek, Lara Baticic, Tamara Braut, Vlatka Sotosek
Biomolecules.2024; 14(8): 925. CrossRef
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy
Kamal S. Saini, Sasikala Somara, Heidi C. Ko, Purva Thatai, Angela Quintana, Zachary D. Wallen, Michelle F. Green, Ravi Mehrotra, Sandra McGuigan, Lingjuan Pang, Soma Das, Kavita Yadav, Dobrica Neric, Luca Cantini, Chinmayee Joshi, Kazuya Iwamoto, Sudha D
Frontiers in Oncology.2024;[Epub] CrossRef
Massive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review
Alfons Nadal, Antonio Cardesa, Abbas Agaimy, Alhadi Almangush, Alessandro Franchi, Henrik Hellquist, Ilmo Leivo, Nina Zidar, Alfio Ferlito
Virchows Archiv.2024; 485(6): 965. CrossRef
FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signaling
Sven Liebig, Martin Neumann, Patricia Silva, Jutta Ortiz-Tanchez, Veronika Schulze, Konstandina Isaakidis, Cornelia Schlee, Michael P. Schroeder, Thomas Beder, Luc G. T. Morris, Timothy A. Chan, Lorenz Bastian, Thomas Burmeister, Stefan Schwartz, Nicola G
Scientific Reports.2023;[Epub] CrossRef
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors
Paula Krone, Annabell Wolff, Julia Teichmann, Johanna Maennicke, Julia Henne, Leonie Engster, Inken Salewski, Wendy Bergmann, Christian Junghanss, Claudia Maletzki
OncoImmunology.2023;[Epub] CrossRef
Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma
Mai Atique, Isis Muniz, Fatemeh Farshadi, Michael Hier, Alex Mlynarek, Marco Macarella, Mariana Maschietto, Belinda Nicolau, Moulay A. Alaoui-Jamali, Sabrina Daniela da Silva
Biomedicines.2023; 12(1): 24. CrossRef
New Treatment Development for Larynx Preservation
Susumu Okano
Koutou (THE LARYNX JAPAN).2023; 35(2): 98. CrossRef
Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer
Roberto N. Solis, Dustin A. Silverman, Andrew C. Birkeland
Current Treatment Options in Oncology.2022; 23(2): 254. CrossRef
EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma
Shengjin Dou, Lin Zhang, Chong Wang, Yanli Yao, Wen Jiang, Lulu Ye, Jiang Li, Sicheng Wu, Debin Sun, Xiaoli Gong, Rongrong Li, Guopei Zhu
Frontiers in Immunology.2022;[Epub] CrossRef
Diagnostics of HNSCC Patients: An Analysis of Cell Lines and Patient-Derived Xenograft Models for Personalized Therapeutical Medicine
Ramona Gabriela Ursu, Ionut Luchian, Costin Damian, Elena Porumb-Andrese, Nicolae Ghetu, Roxana Gabriela Cobzaru, Catalina Lunca, Carmen Ripa, Diana Costin, Igor Jelihovschi, Florin Dumitru Petrariu, Luminita Smaranda Iancu
Diagnostics.2022; 12(5): 1071. CrossRef
Unraveling most abundant mutational signatures in head and neck cancer
Michaela Plath, Johanna Gass, Mario Hlevnjak, Qiaoli Li, Bohai Feng, Xavier Pastor Hostench, Matthias Bieg, Lea Schroeder, Dana Holzinger, Marc Zapatka, Kolja Freier, Wilko Weichert, Jochen Hess, Karim Zaoui
International Journal of Cancer.2021; 148(1): 115. CrossRef
Worldwide prevalence of PI3K-AKT-mTOR pathway mutations in head and neck cancer: A systematic review and meta-analysis
Adriana Castelo de Moura, Daniele Xavier Assad, Juliana Amorim dos Santos, Isabela Porto de Toledo, Gustavo Barcelos Barra, Rogerio Moraes Castilho, Cristiane Helena Squarize, Eliete Neves Silva Guerra
Critical Reviews in Oncology/Hematology.2021; 160: 103284. CrossRef
Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
Stijn J. De Keukeleire, Tijl Vermassen, Elien Hilgert, David Creytens, Liesbeth Ferdinande, Sylvie Rottey
Cancers.2021; 13(7): 1714. CrossRef
Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma
Bhumsuk Keam, Jin-Young Park, Jin-Pyo Kim, Gun-Do Kim, Yun-Suk Yu, Sang-Hee Cho, Sangwoo Kim, Hee-Kyung Ahn, Sang-Hoon Chun, Jung-Hye Kwon, Tak Yun, Ji-Won Kim, Ji-Eun Kim, Myung-Ju Ahn, Joo-Hang Kim, Hwan-Jung Yun
Processes.2021; 9(5): 792. CrossRef
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
Teresa Magnes, Sandro Wagner, Dominik Kiem, Lukas Weiss, Gabriel Rinnerthaler, Richard Greil, Thomas Melchardt
International Journal of Molecular Sciences.2021; 22(9): 4981. CrossRef
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim
Cancer Medicine.2021; 10(20): 7012. CrossRef
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma
Nan Jin, Bhumsuk Keam, Janice Cho, Michelle J. Lee, Hye Ryun Kim, Hayarpi Torosyan, Natalia Jura, Patrick K.S. Ng, Gordon B. Mills, Hua Li, Yan Zeng, Zohar Barbash, Gabi Tarcic, Hyunseok Kang, Julie E. Bauman, Mi-Ok Kim, Nathan K. VanLandingham, Danielle
Journal of Clinical Investigation.2021;[Epub] CrossRef
Understanding the Pattern of Oropharyngeal Cancers from North-East Romanian Patients
Ramona Ursu, Simona Giusca, Irene Spiridon, Bianca Manole, Mihai Danciu, Victor Costan, Dragos Palade, Nicolae Ghetu, Paula Toader, Mădălina Vlad, Costin Damian, Elena Porumb-Andrese, Ionut Luchian, Luminița Iancu
Applied Sciences.2021; 11(24): 12079. CrossRef
Immunologic and immunogenomic aspects of tumor progression
Andrea Ladányi, József Tímár
Seminars in Cancer Biology.2020; 60: 249. CrossRef
Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer
Thomas C. Westbrook, Ian S. Hagemann, Jessica Ley, Kevin Chen, Kevin Palka, Jingxia Liu, Ling Chen, Peter Oppelt, Douglas Adkins
Medical Oncology.2020;[Epub] CrossRef
Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation
Martijn van der Heijden, Paul B. M. Essers, Monique C. de Jong, Reinout H. de Roest, Sebastian Sanduleanu, Caroline V. M. Verhagen, Olga Hamming-Vrieze, Frank Hoebers, Philippe Lambin, Harry Bartelink, C. René Leemans, Marcel Verheij, Ruud H. Brakenhoff,
Frontiers in Oncology.2020;[Epub] CrossRef
Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
Min Hwan Kim, Jae-Hwan Kim, Ji Min Lee, Jae Woo Choi, Dongmin Jung, Hojin Cho, Hyundeok Kang, Min Hee Hong, Su Jin Heo, Se Heon Kim, Eun Chang Choi, Da Hee Kim, Young Min Park, Sangwoo Kim, Sun Och Yoon, Yoon Woo Koh, Byoung Chul Cho, Hye Ryun Kim
British Journal of Cancer.2020; 122(11): 1649. CrossRef
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
Han Na Kang, Jae-Hwan Kim, A-Young Park, Jae Woo Choi, Sun Min Lim, Jinna Kim, Eun Joo Shin, Min Hee Hong, Kyoung-Ho Pyo, Mi Ran Yun, Dong Hwi Kim, Hanna Lee, Sun Och Yoon, Da Hee Kim, Young Min Park, Hyung Kwon Byeon, Inkyung Jung, Soonmyung Paik, Yoon W
BMC Cancer.2020;[Epub] CrossRef
Impact of genetic variants in clinical outcome of a cohort of patients with oropharyngeal squamous cell carcinoma
Ana Carolina de Carvalho, Sandra Perdomo, Wellington dos Santos, Gabriela Carvalho Fernandes, Lais Machado de Jesus, Raiany Santos Carvalho, Cristovam Scapulatempo-Neto, Gisele Caravina de Almeida, Bruna Pereira Sorroche, Lidia Maria Rebolho Batista Arant
Scientific Reports.2020;[Epub] CrossRef
Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma
Hyun Chang, Yun-Gyoo Lee, Yoon Ho Ko, Jang Ho Cho, Jong-Kwon Choi, Keon Uk Park, Eun Joo Kang, Keun-Wook Lee, Sun Min Lim, Jin-Soo Kim, Hyun Woo Lee, Min Kyoung Kim, In Gyu Hwang, Sangwoo Kim, Byung-Ho Nam, Hye Ryun Kim
Cancers.2020; 12(7): 1777. CrossRef
Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
Hye Ryun Kim, Han Na Kang, Mi Ran Yun, Kwon Young Ju, Jae Woo Choi, Dong Min Jung, Kyoung Ho Pyo, Min Hee Hong, Myoung-Ju Ahn, Jong-Mu Sun, Han Sang Kim, Jinna Kim, Jinseon Yoo, Kyu Ryung Kim, Yoon Woo Koh, Se Heon Kim, Eun Chang Choi, Sun Ock Yoon, Hyo S
British Journal of Cancer.2020; 123(12): 1720. CrossRef
Mutationssignaturen beim Kopf- und Hals-Tumor
M. Plath, J. Hess, K. Zaoui
HNO.2020; 68(12): 922. CrossRef
BAMixChecker: an automated checkup tool for matched sample pairs in NGS cohort
Hein Chun, Sangwoo Kim, Inanc Birol
Bioinformatics.2019; 35(22): 4806. CrossRef
Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
Panagiota Economopoulou, Remco de Bree, Ioannis Kotsantis, Amanda Psyrri
Frontiers in Oncology.2019;[Epub] CrossRef
A Review of HPV-Related Head and Neck Cancer
Kazuhiro Kobayashi, Kenji Hisamatsu, Natsuko Suzui, Akira Hara, Hiroyuki Tomita, Tatsuhiko Miyazaki
Journal of Clinical Medicine.2018; 7(9): 241. CrossRef

15,198 View
649 Download
35 Web of Science
35 Crossref

Lifestyle Risk Prediction Model for Prostate Cancer in a Korean Population: Sung Han Kim, Sohee Kim, Jae Young Joung, Whi-An Kwon, Ho Kyung Seo, Jinsoo Chung, Byung-Ho Nam, Kang Hyun Lee; Cancer Res Treat. 2018;50(4):1194-1202. Published online December 21, 2017; DOI: https://doi.org/10.4143/crt.2017.484

Abstract PDF Supplementary Material PubReader ePub

Purpose
The use of prostate-specific antigen as a biomarker for prostate cancer (PC) has been controversial and is, therefore, not used by many countries in their national health screening programs. The biological characteristics of PC in East Asians including Koreans and Japanese are different from those in the Western populations. Potential lifestyle risk factors for PC were evaluated with the aim of developing a risk prediction model.
Materials and Methods
A total of 1,179,172 Korean men who were cancer free from 1996 to 1997, had taken a physical examination, and completed a lifestyle questionnaire, were enrolled in our study to predict their risk for PC for the next eight years, using the Cox proportional hazards model. The model’s performance was evaluated using the C-statistic and Hosmer‒Lemeshow type chi-square statistics.
Results
The risk prediction model studied age, height, body mass index, glucose levels, family history of cancer, the frequency of meat consumption, alcohol consumption, smoking status, and physical activity, which were all significant risk factors in a univariate analysis. The model performed very well (C statistic, 0.887; 95% confidence interval, 0.879 to 0.895) and estimated an elevated PC risk in patients who did not consume alcohol or smoke, compared to heavy alcohol consumers (hazard ratio [HR], 0.78) and current smokers (HR, 0.73) (p < 0.001).
Conclusion
This model can be used for identifying Korean and other East Asian men who are at a high risk for developing PC, as well as for cancer screening and developing preventive health strategies.

Citations

Citations to this article as recorded by

To Drink or Not to Drink? Investigating Alcohol’s Impact on Prostate Cancer Risk
Aris Kaltsas, Michael Chrisofos, Evangelos N. Symeonidis, Athanasios Zachariou, Marios Stavropoulos, Zisis Kratiras, Ilias Giannakodimos, Asterios Symeonidis, Fotios Dimitriadis, Nikolaos Sofikitis
Cancers.2024; 16(20): 3453. CrossRef
Machine learning algorithms that predict the risk of prostate cancer based on metabolic syndrome and sociodemographic characteristics: a prospective cohort study
Tao Thi Tran, Jeonghee Lee, Junetae Kim, Sun-Young Kim, Hyunsoon Cho, Jeongseon Kim
BMC Public Health.2024;[Epub] CrossRef
Combinations of lifestyle behaviors and cancer risk among Korean adults
Ngoc Minh Luu, Thi Tra Bui, Thi Phuong Thao Tran, Thi Huyen Trang Nguyen, Jin-Kyoung Oh
Scientific Reports.2023;[Epub] CrossRef
Cigarette smoking and prostate cancer: A systematic review and meta-analysis of prospective cohort studies
Sarah Al-Fayez, Ashraf El-Metwally
Tobacco Induced Diseases.2023; 21(February): 1. CrossRef
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Taewon Hwang, Hyungseok Oh, Jung Ah Lee, Eo Jin Kim
BMC Urology.2023;[Epub] CrossRef
Association Between Red and Processed Meat Consumption and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis
Saeedeh Nouri-Majd, Asma Salari-Moghaddam, Azadeh Aminianfar, Bagher Larijani, Ahmad Esmaillzadeh
Frontiers in Nutrition.2022;[Epub] CrossRef
Alcohol and Prostate Cancer: Time to Draw Conclusions
Amanda J. Macke, Armen Petrosyan
Biomolecules.2022; 12(3): 375. CrossRef
Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis
Yan Jin, Jae Hung Jung, Woong Kyu Han, Eu Chang Hwang, Yoonmi Nho, Narae Lee, Ji Eun Yun, Kwang Suk Lee, Sang Hyub Lee, Hakmin Lee, Su-Yeon Yu
Investigative and Clinical Urology.2022; 63(3): 251. CrossRef
Association between Relative Preference for Vegetables and Meat and Cancer Incidence in Korean Adults: A Nationwide Population-based Retrospective Cohort Study
Ga-Eun Yie, An Na Kim, Hyun Jeong Cho, Minji Kang, Sungji Moon, Inah Kim, Kwang-Pil Ko, Jung Eun Lee, Sue K. Park
Korean Journal of Community Nutrition.2021; 26(3): 211. CrossRef
Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review
Antonio Bandala-Jacques, Kevin Daniel Castellanos Esquivel, Fernanda Pérez-Hurtado, Cristobal Hernández-Silva, Nancy Reynoso-Noverón
JMIR Cancer.2021; 7(3): e30430. CrossRef
Personalized 5-Year Prostate Cancer Risk Prediction Model in Korea Based on Nationwide Representative Data
Yohwan Yeo, Dong Wook Shin, Jungkwon Lee, Kyungdo Han, Sang Hyun Park, Keun Hye Jeon, Jungeun Shin, Aesun Shin, Jinsung Park
Journal of Personalized Medicine.2021; 12(1): 2. CrossRef
Lifestyles, health habits, and prostate cancer
Tomoyuki Kawada
Journal of Cancer Research and Clinical Oncology.2020; 146(6): 1623. CrossRef
Combination possibility and deep learning model as clinical decision-aided approach for prostate cancer
Okyaz Eminaga, Omran Al-Hamad, Martin Boegemann, Bernhard Breil, Axel Semjonow
Health Informatics Journal.2020; 26(2): 945. CrossRef
Tailored Biofunctionalized Biosensor for the Label-Free Sensing of Prostate-Specific Antigen
Sachin Mishra, Eun-Seong Kim, Parshant Kumar Sharma, Zhi-Ji Wang, Sung-Hyun Yang, Ajeet Kumar Kaushik, Cong Wang, Yang Li, Nam-Young Kim
ACS Applied Bio Materials.2020; 3(11): 7821. CrossRef
A Study on Risk Factors of the Incidence of Prostate Cancer Using National Health Insurance Service: Effects of BMI on Age
Hye Sim Kim, Tae Hwa Go, Dae Ryong Kang, Jae Hung Jung, Sung Won Kwon, Sae Chul Kim, Jae Mann Song, Hyun Chul Chung, Sang Baek Koh
Journal of Health Informatics and Statistics.2019; 44(4): 410. CrossRef

10,113 View
258 Download
13 Web of Science
15 Crossref

Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status: Youngjoo Lee, Ji-Youn Han, Sung Ho Moon, Byung-Ho Nam, Kun Young Lim, Geon Kook Lee, Heung Tae Kim, Tak Yun, Hye Jin An, Jin Soo Lee; Cancer Res Treat. 2017;49(4):981-989. Published online January 6, 2017; DOI: https://doi.org/10.4143/crt.2016.522

Abstract PDF Supplementary Material PubReader ePub

Purpose
Concurrent chemoradiotherapy (CCRT) is the standard care for stage III non-small cell lung cancer (NSCLC) patients; however, a more effective regimen is needed to improve the outcome by better controlling occult metastases. We conducted two parallel randomized phase II studies to incorporate erlotinib or irinotecan-cisplatin (IP) into CCRT for stage III NSCLC depending on epidermal growth factor receptor (EGFR) mutation status.
Materials and Methods
Patients with EGFR-mutant tumors were randomized to receive three cycles of erlotinib first and then either CCRT with erlotinib followed by erlotinib (arm A) or CCRT with IP only (arm B). Patients with EGFR unknown or wild-type tumors were randomized to receive either three cycles of IP before (arm C) or after CCRT with IP (arm D).
Results
Seventy-three patients were screened and the study was closed early because of slow accrual after 59 patients were randomized. Overall, there were seven patients in arm A, five in arm B, 22 in arm C, and 25 in arm D. The response rate was 71.4% and 80.0% for arm A and B, and 70.0% and 73.9% for arm C and D. The median overall survival (OS) was 39.3 months versus 31.2 months for arm A and B (p=0.442), and 16.3 months versus 25.3 months for arm C and D (p=0.050). Patients with sensitive EGFR mutations had significantly longer OS than EGFR-wild patients (74.8 months vs. 25.3 months, p=0.034). There were no unexpected toxicities.
Conclusion
Combined-modality treatment by molecular diagnostics is feasible in stage III NSCLC. EGFR-mutant patients appear to be a distinct subset with longer survival.

Citations

Citations to this article as recorded by

Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
Terufumi Kato, Ignacio Casarini, Manuel Cobo, Corinne Faivre-Finn, Fiona Hegi-Johnson, Shun Lu, Mustafa Özgüroğlu, Suresh S. Ramalingam
Lung Cancer.2024; 187: 107414. CrossRef
The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC
Allison E B Chang, Andrew J Piper-Vallillo, Raymond H Mak, Michael Lanuti, Alona Muzikansky, Julia Rotow, Pasi A Jänne, Mari Mino-Kenudson, Scott Swanson, Cameron D Wright, David Kozono, Paul Marcoux, Zofia Piotrowska, Lecia V Sequist, Henning Willers
The Oncologist.2024; 29(7): 609. CrossRef
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario
Valeria Fuorivia, Ilaria Attili, Carla Corvaja, Riccardo Asnaghi, Ambra Carnevale Schianca, Pamela Trillo Aliaga, Ester Del Signore, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Current Oncology.2024; 31(9): 5121. CrossRef
Comparison of treatment regimens for unresectable stage III epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer
Xin Dai, Qian Xu, Lei Sheng, Xue Zhang, Miao Huang, Song Li, Kai Huang, Jiahui Chu, Jian Wang, Jisheng Li, Yanguo Liu, Jianyuan Zhou, Shulun Nie, Lian Liu
Chinese Medical Journal.2024;[Epub] CrossRef
Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer
Jerold Loh, Jia Li Low, Manavi Sachdeva, Peter QJ Low, Rachel Su Jen Wong, Yiqing Huang, Puey Ling Chia, Ross A Soo
Expert Review of Anticancer Therapy.2023; 23(9): 913. CrossRef
Peptide-Hydrogel Nanocomposites for Anti-Cancer Drug Delivery
Farid Hajareh Haghighi, Roya Binaymotlagh, Ilaria Fratoddi, Laura Chronopoulou, Cleofe Palocci
Gels.2023; 9(12): 953. CrossRef
Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1‐STAT1 loop in lung adenocarcinoma
Wei‐Chao Liao, Tsung‐Jen Lin, Yu‐Chin Liu, Yu‐Shan Wei, Guan‐Ying Chen, Hsiang‐Pu Feng, Yi‐Feng Chang, Hsin‐Tzu Chang, Chih‐Liang Wang, Hsinag‐Cheng Chi, Chun‐I Wang, Kwang‐Huei Lin, Wei‐Ting Ou Yang, Chia‐Jung Yu
Cancer Science.2022; 113(1): 205. CrossRef
Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial
Ligang Xing, Gang Wu, Luhua Wang, Jiancheng Li, Jianhua Wang, Zhiyong Yuan, Ming Chen, Yaping Xu, Xiaolong Fu, Zhengfei Zhu, You Lu, Chun Han, Tingyi Xia, Conghua Xie, Guang Li, Shenglin Ma, Bing Lu, Qin Lin, Guangying Zhu, Baolin Qu, Wanqi Zhu, Jinming Y
International Journal of Radiation Oncology*Biology*Physics.2021; 109(5): 1349. CrossRef
A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer
M. Or, B. Liu, J. Lam, S. Vinod, W. Xuan, R. Yeghiaian-Alvandi, E. Hau
Scientific Reports.2021;[Epub] CrossRef
Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?
Aruz Mesci, Theodoros Tsakiridis, Anand Swaminath
Journal of Thoracic Oncology.2021; 16(10): 1607. CrossRef
Experiences of patients with lung cancer receiving concurrent chemo-radiotherapy
Choi Eunsook, Park Sunhee
Clinical Journal of Nursing Care and Practice.2021; 5(1): 015. CrossRef
Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer
Miguel J Sotelo, José Luis García, Cesar Torres-Mattos, Héctor Milián, Carlos Carracedo, María Ángeles González-Ruiz, Xabier Mielgo-Rubio, Juan Carlos Trujillo-Reyes, Felipe Couñago
World Journal of Clinical Oncology.2021; 12(10): 912. CrossRef
PLGA nanoparticle-reinforced supramolecular peptide hydrogels for local delivery of multiple drugs with enhanced synergism
Can Wu, Chunlu Wang, Lu Sun, Keming Xu, Wenying Zhong
Soft Matter.2020; 16(46): 10528. CrossRef
Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials
Ruifeng Liu, Shihong Wei, Qiuning Zhang, Xueliang Zhang, Hongtao Luo, Jinhui Tian, Yi Li, Long Ge, Xiaohu Wang
Medicine.2019; 98(29): e16427. CrossRef
Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?
Sanjal Desai, Chul Kim, Irina Veytsman
Current Oncology Reports.2019;[Epub] CrossRef

10,387 View
311 Download
14 Web of Science
15 Crossref

What Is the Ideal Tumor Regression Grading System in Rectal Cancer Patients after Preoperative Chemoradiotherapy?: Soo Hee Kim, Hee Jin Chang, Dae Yong Kim, Ji Won Park, Ji Yeon Baek, Sun Young Kim, Sung Chan Park, Jae Hwan Oh, Ami Yu, Byung-Ho Nam; Cancer Res Treat. 2016;48(3):998-1009. Published online October 22, 2015; DOI: https://doi.org/10.4143/crt.2015.254

Abstract PDF PubReader ePub

Purpose
Tumor regression grade (TRG) is predictive of therapeutic response in rectal cancer patients after chemoradiotherapy (CRT) followed by curative resection. However, various TRG systems have been suggested, with subjective categorization, resulting in interobserver variability. This study compared the prognostic validity of four different TRG systems in order to identify the most ideal TRG system. Materials and Methods This study included 933 patients who underwent preoperative CRT and curative resection. Primary tumors alone were graded according to the American Joint Committee on Cancer (AJCC), Dworak, and Ryan TRG systems, and both primary tumors and regional lymph nodes were graded according to a modified Dworak TRG system. The ability of each TRG system to predict recurrence-free survival (RFS) and overall survival (OS) was analyzed using chisquare and C statistics.
Results
All four TRG systems were significantly predictive of both RFS and OS (p < 0.001 each), however none was a better predictor of prognosis than ypStage. Among the four TRGs, the mDworak TRG system was a better predictor of RFS and OS than the AJCC, Dworak, and Ryan TRG systems, and both the chi-square and C statistics were higher for the former, although the differences were not statistically significant. The combination of ypStage and the modified Dworak TRG better predicted RFS and OS than ypStage alone. Conclusion The modified Dworak TRG system for evaluation of entire tumors including regional lymph nodes is a better predictor of survival than current TRG systems for evaluation of the primary tumor alone.

Citations

Citations to this article as recorded by

Prognostic Value of Tumor Regression Grade Combined with Pathological Lymph Node Status in Initially Node-Positive Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy
Dakui Luo, Yajie Chen, Zhouyu Luo, Huangbo Gong, Qingguo Li, Xinxiang Li
Journal of Investigative Surgery.2025;[Epub] CrossRef
Interpretation of Complete Tumor Response on MRI Following Chemoradiotherapy of Rectal Cancer: Inter-Reader Agreement and Associated Factors in Multi-Center Clinical Practice
Hae Young Kim, Seung Hyun Cho, Jong Keon Jang, Bohyun Kim, Chul-min Lee, Joon Seok Lim, Sung Kyoung Moon, Soon Nam Oh, Nieun Seo, Seong Ho Park
Korean Journal of Radiology.2024; 25(4): 351. CrossRef
Evaluating complete response prediction rates in locally advanced rectal cancer with different radiomics segmentation approaches
Gizem Kaval, Merve Gulbiz Dagoglu Kartal, Sena Azamat, Eda Cingoz, Gokhan Ertas, Sule Karaman, Basak Kurtuldu, Metin Keskin, Neslihan Berker, Senem Karabulut, Ethem Nezih Oral, Nergiz Dagoglu Sakin
Pathology and Oncology Research.2024;[Epub] CrossRef
Regressionsgrading gastrointestinaler Tumoren
Doreen Maria Gisder, Andrea Tannapfel, Iris Tischoff
Die Gastroenterologie.2024; 19(3): 234. CrossRef
Rectal Cancer Survival for Residual Carcinoma In Situ Vs. Pathologic Complete Response After Neoadjuvant Therapy
Nathan M. Kohrman, Jordan R. Wlodarczyk, Li Ding, Nicholas P. McAndrew, Sandra D. Algaze, Kyle G. Cologne, Sang W. Lee, Sarah E Koller
Diseases of the Colon & Rectum.2024;[Epub] CrossRef
Predictive value of flexible proctosigmoidoscopy and laboratory findings for complete clinical responses after neoadjuvant chemoradiotherapy in patients with locally advanced primary rectal cancer: a retrospective cohort study
Alireza Hadizadeh, Hamed Kazemi-Khaledi, Mohammad-Sadegh Fazeli, Seyed-Mohsen Ahmadi-Tafti, Amir Keshvari, Reza Akbari-Asbagh, Mohammad-Reza Keramati, Alireza Kazemeini, Amir-Reza Fazeli, Behnam Behboudi, Mohammadamin Parsaei
International Journal of Colorectal Disease.2024;[Epub] CrossRef
Are the tumor microenvironment characteristics of pretreatment biopsy specimens of colorectal cancer really effectively predict the efficacy of neoadjuvant therapy: A retrospective multicenter study
Bingbing Li, Longjiao Chen, Yichun Huang, Meng Wu, Weilan Fang, Xin Zou, Yihong Zheng, Qiuxiang Xiao
Medicine.2024; 103(35): e39429. CrossRef
Outcomes of rectal cancer treatment in rural Australia and New Zealand: analysis of the bowel cancer outcomes registry
Ishmam Murshed, Tessa L. Dinger, Duveke P. E. de Gaay Fortman, Luke Traeger, Sergei Bedrikovetski, Andrew Hunter, Hidde M. Kroon, Tarik Sammour
ANZ Journal of Surgery.2024; 94(10): 1823. CrossRef
Relationship Between Neoadjuvant Chemoradiotherapy Response and Mesorectum Volume in Rectum Cancer
Ramazan Saygın Kerimoğlu, Ebru Esen, Mustafa Saraçoğlu, İbrahim Babalıoğlu, Bekir Turgut, İlknur Küçükosmanoğlu, Osman Doğru
Acta Haematologica Oncologica Turcica.2024; : 44. CrossRef
Molecular Mechanism of Radioresponsiveness in Colorectal Cancer: A Systematic Review
Matthew Lau, Md Islam Khan, Helen Law
Genes.2024; 15(10): 1257. CrossRef
Tumor Immune Microenvironment Biomarkers for Recurrence Prediction in Locally Advanced Rectal Cancer Patients after Neoadjuvant Chemoradiotherapy
Jun-Eul Hwang, Sung-Sun Kim, Hyun-Jin Bang, Hyeon-Jong Kim, Hyun-Jeong Shim, Woo-Kyun Bae, Ik-Joo Chung, Eun-Gene Sun, Taebum Lee, Chan-Young Ock, Jeong-Seok Nam, Sang-Hee Cho
Cancers.2024; 16(19): 3353. CrossRef
Neoadjuvant chemotherapy in locally advanced colon cancer: A systematic review with proportional meta-analysis
K. van den Berg, I.E.G. van Hellemond, J.M.W.E. Willems, J.W.A. Burger, H.J.T. Rutten, G.J. Creemers
European Journal of Surgical Oncology.2024; : 109560. CrossRef
A Novel Engineered AAV-Based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors
Kevin Chih-Yang Huang, Chia-Ying Lai, Wei-Ze Hung, Hsin-Yu Chang, Pei-Chun Lin, Shu-Fen Chiang, Tao-Wei Ke, Ji-An Liang, An-Cheng Shiau, Pei-Chen Yang, William Tzu-Liang Chen, K.S. Clifford Chao
Cancer Immunology Research.2023; 11(1): 123. CrossRef
Does Pathological Complete Response after Neoadjuvant Therapy Influence Postoperative Morbidity in Rectal Cancer after Transanal Total Mesorectal Excision?
Martin Svoboda, Vladimír Procházka, Tomáš Grolich, Tomáš Pavlík, Monika Mazalová, Zdeněk Kala
Journal of Gastrointestinal Cancer.2023; 54(2): 528. CrossRef
MRI‐Based Artificial Intelligence in Rectal Cancer
Chinting Wong, Yu Fu, Mingyang Li, Shengnan Mu, Xiaotong Chu, Jiahui Fu, Chenghe Lin, Huimao Zhang
Journal of Magnetic Resonance Imaging.2023; 57(1): 45. CrossRef
Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non‐responders' tumor tissue
Tamara Babic, Vasiliki Lygirou, Jovana Rosic, Marko Miladinov, Aleksandra Djikic Rom, Eirini Baira, Rafael Stroggilos, Eftychia Pappa, Jerome Zoidakis, Zoran Krivokapic, Aleksandra Nikolic
PROTEOMICS – Clinical Applications.2023;[Epub] CrossRef
Comparison of the diagnostic performance of changes in signal intensity and volume from multiparametric MRI for assessing response of rectal cancer to neoadjuvant chemoradiotherapy
Zhengwu Tan, Lan Cheng, Lingling Xie, Lan Zhang, Zhenyu Lin, Ping Han, Xin Li
Asia-Pacific Journal of Clinical Oncology.2023; 19(3): 327. CrossRef
Carbonic Anhydrase IX Expression and Treatment Response Measured in Rectal Adenocarcinoma Following Neoadjuvant Chemo-Radiotherapy
Emese Sarolta Bádon, Lívia Beke, Attila Mokánszki, Csilla András, Gábor Méhes
International Journal of Molecular Sciences.2023; 24(3): 2581. CrossRef
Benefits of Adjuvant Chemotherapy for Clinical T3-4N0 Rectal Cancer After Preoperative Chemoradiotherapy
Hyun Jin Bang, Hyun Jeong Shim, Jun Eul Hwang, Woo Kyun Bae, Ik Joo Chung, Sang Hee Cho
Chonnam Medical Journal.2023; 59(1): 76. CrossRef
The prognostic role of tumor budding and tumor-stroma ratio in pulmonary metastasis of colorectal carcinoma
Topias Karjula, Niko Kemi, Anne Niskakangas, Olli Mustonen, Iiris Puro, Vesa-Matti Pohjanen, Teijo Kuopio, Hanna Elomaa, Maarit Ahtiainen, Jukka-Pekka Mecklin, Toni T. Seppälä, Erkki-Ville Wirta, Eero Sihvo, Juha P. Väyrynen, Fredrik Yannopoulos, Olli Hel
European Journal of Surgical Oncology.2023; 49(7): 1298. CrossRef
An investigation into tumor regression grade as a parameter for locally advanced rectal cancer and 5-year overall survival rate
Supparerk Laohawiriyakamol, Wongsakorn Chaochankit, Worawit Wanichsuwan, Kanet Kanjanapradit, Teeranan Laohawiriyakamol
Annals of Coloproctology.2023; 39(1): 59. CrossRef
Deep learning of endoscopic features for the assessment of neoadjuvant therapy response in locally advanced rectal cancer
Anqi Wang, Jieli Zhou, Gang Wang, Beibei Zhang, Hongyi Xin, Haiyang Zhou
Asian Journal of Surgery.2023; 46(9): 3568. CrossRef
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy alone for patients with locally advanced rectal cancer: a propensity-score-matched analysis combined with SEER validation
Jingjing Wu, Mingzhe Huang, Yuanhui Wu, Yisong Hong, Linbin Cai, Rongzhao He, Yanxin Luo, Puning Wang, Meijin Huang, Jinxin Lin
Journal of Cancer Research and Clinical Oncology.2023; 149(11): 8897. CrossRef
A multi-class classification algorithm based on hematoxylin-eosin staining for neoadjuvant therapy in rectal cancer: a retrospective study
Yihan Wu, Xiaohua Liu, Fang Liu, Yi Li, Xiaomin Xiong, Hao Sun, Bo Lin, Yu Li, Bo Xu
PeerJ.2023; 11: e15408. CrossRef
Early Age of Onset Is an Independent Predictor for a Worse Response to Neoadjuvant Therapies in Sporadic Rectal Cancer Patients
Caterina Foppa, Annalisa Maroli, Antonio Luberto, Carlotta La Raja, Paola Spaggiari, Cristiana Bonifacio, Stefano De Zanet, Marco Montorsi, Salvatore Piscuoglio, Luigi Maria Terracciano, Armando Santoro, Antonino Spinelli
Cancers.2023; 15(14): 3750. CrossRef
Metformin increases pathological responses to rectal cancers with neoadjuvant chemoradiotherapy: a systematic review and meta-analysis
I-Li Lai, Jeng-Fu You, Wen-Sy Tsai, Yu-Jen Hsu, Yih-Jong Chern, Ming-Ying Wu
World Journal of Surgical Oncology.2023;[Epub] CrossRef
Risk factors for lateral pelvic lymph node metastasis in patients with lower rectal cancer: a systematic review and meta-analysis
De-xing Zeng, Zhou Yang, Ling Tan, Meng-ni Ran, Zi-lin Liu, Jiang-wei Xiao
Frontiers in Oncology.2023;[Epub] CrossRef
Clinical predictors of rectal cancer response after neo-adjuvant (Chemo)Radiotherapy in Australia and New Zealand: Analysis of the Bi-National Colorectal Cancer Audit (BCCA)
Jianliang Liu, Justin Y.T. Lee, Sergei Bedrikovetski, Luke Traeger, James W. Moore, Joanne L. Perry, Hidde M. Kroon, Tarik Sammour
European Journal of Surgical Oncology.2023; 49(11): 107070. CrossRef
Pancreatic ductal adenocarcinoma complete regression after preoperative chemotherapy: Surgical results in a small series
Domenico Pinelli, Andrea Micalef, Barbara Merelli, Rosangela Trezzi, Annalisa Amaduzzi, Stefano Agnesi, Michela Guizzetti, Stefania Camagni, Veronica Fedele, Michele Colledan
Cancer Treatment and Research Communications.2023; 37: 100770. CrossRef
The ypT may better predict the efficacy of neoadjuvant chemoradiotherapy than tumor regression grade in locally advanced rectal cancer patients diagnosed ypT1-4N0
Yujun Cui, Xinzhi Liu, Shuai Li, Hongzhi Wang, Yirong Xiang, Yangzi Zhang, Maxiaowei Song, Jianhao Geng, Zhiyan Liu, Huajing Teng, Xianggao Zhu, Yong Cai, Yongheng Li, Weihu Wang
Clinical and Translational Oncology.2023; 26(4): 1012. CrossRef
Grading der Tumorregression gastrointestinaler Karzinome nach neoadjuvanter Therapie
Drolaiz Liu, Rupert Langer
Der Pathologe.2022; 43(1): 51. CrossRef
Deeper sections reveal residual tumor cells in rectal cancer specimens diagnosed with pathological complete response following neoadjuvant treatment
Lasse Slumstrup, Susanne Eiholm, Astrid Louise Bjørn Bennedsen, Dea Natalie Munch Jepsen, Ismail Gögenur, Anne-Marie Kanstrup Fiehn
Virchows Archiv.2022; 480(5): 1041. CrossRef
MRI Radiomics Model Predicts Pathologic Complete Response of Rectal Cancer Following Chemoradiotherapy
Jaeseung Shin, Nieun Seo, Song-Ee Baek, Nak-Hoon Son, Joon Seok Lim, Nam Kyu Kim, Woong Sub Koom, Sungwon Kim
Radiology.2022; 303(2): 351. CrossRef
Antitumor Effect and Induced Immune Response Following Exposure of Hexaminolevulinate and Blue Light in Combination with Checkpoint Inhibitor in an Orthotopic Model of Rat Bladder Cancer
Laureline Lamy, Jacques Thomas, Agnès Leroux, Jean-François Bisson, Kari Myren, Aslak Godal, Gry Stensrud, Lina Bezdetnaya
Biomedicines.2022; 10(3): 548. CrossRef
High Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio and Low Lymphocyte Levels Are Correlated With Worse Pathological Complete Response Rates
Serdar Karakaya, İbrahim Karadağ, Mehmet Emin Yılmaz, Ömür Berna Çakmak Öksüzoğlu
Cureus.2022;[Epub] CrossRef
Development of a method for digital assessment of tumor regression grade in patients with rectal cancer following neoadjuvant therapy
Dea Natalie Munch Jepsen, Henrik Høeg, Jeppe Thagaard, Julie Sparholt Walbech, Ismail Gögenur, Anne-Marie Kanstrup Fiehn
Journal of Pathology Informatics.2022; 13: 100152. CrossRef
The reduction of 18F-FDG uptake ability of tumor tissue after neoadjuvant chemoradiotherapy in locally advanced rectal cancer can effectively reflect the degree of tumor regression
Fengpeng Wu, Xiaoxiao Zhang, Congrong Yang, Kanghua Wang, Linlin Xiao, Chaoxi Zhou, Xinming Zhao, Guiying Wang
Frontiers in Oncology.2022;[Epub] CrossRef
Reduced field-of-view versus full field-of-view diffusion-weighted imaging for the evaluation of complete response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer
Siwon Jang, Jeong Min Lee, Jeong Hee Yoon, Jae Seok Bae
Abdominal Radiology.2021; 46(4): 1468. CrossRef
Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer
Peige Zhou, Paolo Goffredo, Timothy Ginader, Dakota Thompson, Jennifer Hrabe, Irena Gribovskaja‐Rupp, Muneera Kapadia, Imran Hassan
Journal of Surgical Oncology.2021; 123(1): 278. CrossRef
Clinical predictors of response to chemoradiotherapy for rectal cancer as an aid to organ preservation
Jesse Fischer, Tim W. Eglinton, Frank A. Frizelle
ANZ Journal of Surgery.2021; 91(6): 1190. CrossRef
Can the mesorectal fat tissue volume be used as a predictive factor in foreseeing the response to neoadjuvant chemoradiotherapy in rectum cancer? A CT-based preliminary study
Okan Dilek, Huseyin Akkaya, Cenk Parlatan, Tolga Koseci, Zeynel Abidin Tas, Gökhan Soker, Bozkurt Gulek
Abdominal Radiology.2021; 46(6): 2415. CrossRef
Pathological response post neoadjuvant therapy for locally advanced rectal cancer is an independent predictor of survival
Jason On, Joanna Shim, Craig Mackay, Graeme Murray, Leslie Samuel, Craig Parnaby, George Ramsay
Colorectal Disease.2021; 23(6): 1326. CrossRef
Complete pathological response in rectal cancer utilising novel treatment strategies for neo-adjuvant therapy: A systematic review
K. Wilson, M. Flood, V. Narasimhan, T. Pham, S. Warrier, R. Ramsay, M. Michael, A. Heriot
European Journal of Surgical Oncology.2021; 47(8): 1862. CrossRef
Contemporary snapshot of tumor regression grade (TRG) distribution in locally advanced rectal cancer: a cross sectional multicentric experience
Paola Germani, Francesca Di Candido, Daniel Léonard, Dajana Cuicchi, Ugo Elmore, Marco Ettore Allaix, Vittoria Pia Barbieri, Laura D’Allens, Seraina Faes, Marika Milani, Damiano Caputo, Carmen Martinez, Jan Grosek, Valerio Caracino, Niki Christou, Sapho X
Updates in Surgery.2021; 73(5): 1795. CrossRef
The value of the tumour-stroma ratio for predicting neoadjuvant chemoradiotherapy response in locally advanced rectal cancer: a case control study
Yanting Liang, Yaxi Zhu, Huan Lin, Shenyan Zhang, Suyun Li, Yanqi Huang, Chen Liu, Jinrong Qu, Changhong Liang, Ke Zhao, Zhenhui Li, Zaiyi Liu
BMC Cancer.2021;[Epub] CrossRef
Can histologic features predict neoadjuvant therapy response in rectal adenocarcinoma?
Yuho Ono, Justin M.M. Cates, Raul S. Gonzalez
Pathology - Research and Practice.2021; 226: 153608. CrossRef
A 41-Gene Pair Signature for Predicting the Pathological Response of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiation
Zhengfa Xue, Shuxin Yang, Yun Luo, Hao Cai, Ming He, Youping Ding, Lei Lei, Wei Peng, Guini Hong, You Guo
Frontiers in Medicine.2021;[Epub] CrossRef
Validation of Gene Expression-Based Predictive Biomarkers for Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
Tomoyuki Momma, Hirokazu Okayama, Yasuyuki Kanke, Satoshi Fukai, Hisashi Onozawa, Shotaro Fujita, Wataru Sakamoto, Motonobu Saito, Shinji Ohki, Koji Kono
Cancers.2021; 13(18): 4642. CrossRef
Varying practices in tumor regression grading of gastrointestinal carcinomas after neoadjuvant therapy: results of an international survey
Maria Westerhoff, Marek Osecky, Rupert Langer
Modern Pathology.2020; 33(4): 676. CrossRef
Importance of the neoadjuvant rectal (NAR) score to the outcome of neoadjuvant chemotherapy alone for locally advanced rectal cancer
Toshiki Mukai, Keisuke Uehara, Toshisada Aiba, Atsushi Ogura, Toyonori Tsuzuki, Aya Tanaka, Masanori Sando, Noriyuki Ohara, Yusuke Sato, Norifumi Hattori, Goro Nakayama, Yasuhiro Kodera, Masato Nagino
Surgery Today.2020; 50(8): 912. CrossRef
The Effect of Lymph Nodes’ Histologic Response on Survival Outcomes in Moroccan Patients with Rectal Cancer
Ihsane El Otmani, Fatima El Agy, Mohammed El Abkari, Karim Ibn Majdoub Hassani, Khalid Mazaz, El Bachir Benjelloun, Khalid Ait Taleb, Touria Bouhafa, Zineb Benbrahim, Sidi Adil Ibrahimi, Laila Chbani
International Journal of Surgical Oncology.2020; 2020: 1. CrossRef
Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus
Flávio Roberto Takeda, Francisco Tustumi, Carlos de Almeida Obregon, Gustavo Gonçalves Yogolare, Yasmin Peres Navarro, Vanderlei Segatelli, Rubens Antonio Aissar Sallum, Ulysses Ribeiro Junior, Ivan Cecconello
Annals of Surgical Oncology.2020; 27(4): 1241. CrossRef
Standardized Pathology Report for Colorectal Cancer, 2nd Edition
Baek-hui Kim, Joon Mee Kim, Gyeong Hoon Kang, Hee Jin Chang, Dong Wook Kang, Jung Ho Kim, Jeong Mo Bae, An Na Seo, Ho Sung Park, Yun Kyung Kang, Kyung-Hwa Lee, Mee Yon Cho, In-Gu Do, Hye Seung Lee, Hee Kyung Chang, Do Youn Park, Hyo Jeong Kang, Jin Hee So
Journal of Pathology and Translational Medicine.2020; 54(1): 1. CrossRef
Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer
Jason K. Douglas, Rose E. Callahan, Zachary A. Hothem, Craig S. Cousineau, Samer Kawak, Bryan J. Thibodeau, Shelli Bergeron, Wei Li, Claire E. Peeples, Harry J. Wasvary
Molecular & Cellular Oncology.2020; 7(3): 1716618. CrossRef
53BP1 expression and immunoscore are associated with the efficacy of neoadjuvant chemoradiotherapy for rectal cancer
Ai Huang, Yong Xiao, Chunfen Peng, Tao Liu, Zhenyu Lin, Qin Yang, Tao Zhang, Jun Liu, Hong Ma
Strahlentherapie und Onkologie.2020; 196(5): 465. CrossRef
Predictors of pathological response and clinical outcome following chemoradiation for locally advanced rectal cancer — a systematic review
Erica Amaral, Maria Bernardes, Sara Ribeiro, Beatriz Rosa, Ana Pereira, Sandra F. Martins
Journal of Coloproctology.2020; 40(03): 278. CrossRef
The effect of radiotherapy on rectal cancer: a histopathological appraisal and prognostic indicators
Mohammad AlQudah, Emil Salmo, Najib Haboubi
Radiation Oncology Journal.2020; 38(2): 77. CrossRef
Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial
Mahdi Aghili, Nastaran Khalili, Neda Khalili, Mohammad Babaei, Farshid Farhan, Peiman Haddad, Samaneh Salarvand, Amir Keshvari, Mohammad Sadegh Fazeli, Negin Mohammadi, Reza Ghalehtaki
Radiation Oncology Journal.2020; 38(2): 119. CrossRef
Pre-Treatment T2-WI Based Radiomics Features for Prediction of Locally Advanced Rectal Cancer Non-Response to Neoadjuvant Chemoradiotherapy: A Preliminary Study
Bianca Petresc, Andrei Lebovici, Cosmin Caraiani, Diana Sorina Feier, Florin Graur, Mircea Marian Buruian
Cancers.2020; 12(7): 1894. CrossRef
Preoperative Fibrinogen-Albumin Ratio Index (FARI) is a Reliable Prognosis and Chemoradiotherapy Sensitivity Predictor in Locally Advanced Rectal Cancer Patients Undergoing Radical Surgery Following Neoadjuvant Chemoradiotherapy

Siyi Lu, Zhenzhen Liu, Xin Zhou, Bingyan Wang, Fei Li, Yanpeng Ma, Wendong Wang, Junren Ma, Yuxia Wang, Hao Wang, Wei Fu
Cancer Management and Research.2020; Volume 12: 8555. CrossRef
Staging of Locally Advanced Rectal Cancer Beyond TME
Deborah S. Keller
Clinics in Colon and Rectal Surgery.2020; 33(05): 258. CrossRef
Tumor Regression in Lymph Node Metastases of Esophageal Adenocarcinomas after Neoadjuvant Therapy
Marek Osecky, Dino Kröll, Marcus Feith, Daniel Reim, Bastian Dislich, Karen Becker, Rupert Langer
Gastrointestinal Disorders.2020; 2(4): 397. CrossRef
Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer
Chinock Cheong, Jun Sang Shin, Kwang Wook Suh
World Journal of Gastroenterology.2020; 26(44): 7022. CrossRef
MicroRNA Profiling in Oesophageal Adenocarcinoma Cell Lines and Patient Serum Samples Reveals a Role for miR-451a in Radiation Resistance
Frederike Butz, Ann-Kathrin Eichelmann, George C. Mayne, Tingting Wang, Isabell Bastian, Karen Chiam, Shashikanth Marri, Pamela J. Sykes, Bas P. Wijnhoven, Eelke Toxopeus, Michael Z. Michael, Christos S. Karapetis, Richard Hummel, David I. Watson, Damian
International Journal of Molecular Sciences.2020; 21(23): 8898. CrossRef
Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer
Heyu Song, Jiping Zeng, Shrabasti Roychoudhury, Pranjal Biswas, Bhopal Mohapatra, Sutapa Ray, Kayvon Dowlatshahi, Jing Wang, Vimla Band, Geoffrey Talmon, Kishor K. Bhakat
Molecular Cancer Therapeutics.2020; 19(1): 258. CrossRef
Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy
Jung Wook Huh, Hee Cheol Kim, Seok Hyung Kim, Yoon Ah Park, Yong Beom Cho, Seong Hyeon Yun, Woo Yong Lee, Hee Chul Park, Doo Ho Choi, Joon Oh Park, Young Suk Park, Ho-Kyung Chun
Surgery.2019; 165(3): 579. CrossRef
Tumour regression after radiotherapy for rectal cancer – Results from the randomised Stockholm III trial
Johan Erlandsson, Ester Lörinc, Madelene Ahlberg, David Pettersson, Torbjörn Holm, Bengt Glimelius, Anna Martling
Radiotherapy and Oncology.2019; 135: 178. CrossRef
Differences in prognostic relevance of rectal magnetic resonance imaging findings before and after neoadjuvant chemoradiotherapy
Kwang-Seop Song, Dong Woon Lee, Bun Kim, Bo Yun Hur, Min Jung Kim, Min Ju Kim, Chang Won Hong, Sung Chan Park, Hyoung-Chul Park, Dae Kyung Sohn, Byung Chang Kim, Kyung Su Han, Jae Hwan Oh
Scientific Reports.2019;[Epub] CrossRef
A prospective feasibility study evaluating the role of multimodality imaging and liquid biopsy for response assessment in locally advanced rectal carcinoma
Zahra Kassam, Kyle Burgers, Joanna C. Walsh, Ting-Yim Lee, Hon S. Leong, Barbara Fisher
Abdominal Radiology.2019; 44(11): 3641. CrossRef
Pretreatment Blood Biomarkers Predict Pathologic Responses to Neo-Crt in Patients with Locally Advanced Rectal Cancer
Aijie Li, Kewen He, Dong Guo, Chao Liu, Duoying Wang, Xiangkui Mu, Jinming Yu
Future Oncology.2019; 15(28): 3233. CrossRef
Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patients’ Prognosis
Giuseppe N. Fanelli, Fotios Loupakis, Elizabeth Smyth, Marco Scarpa, Sara Lonardi, Salvatore Pucciarelli, Giada Munari, Massimo Rugge, Nicola Valeri, Matteo Fassan
International Journal of Surgical Pathology.2019; 27(8): 816. CrossRef
Translational Potential of MicroRNAs for Preoperative Staging and Prediction of Chemoradiotherapy Response in Rectal Cancer
Tana Machackova, Vladimir Prochazka, Zdenek Kala, Ondrej Slaby
Cancers.2019; 11(10): 1545. CrossRef
Association of tumor differentiation and prognosis in patients with rectal cancer undergoing neoadjuvant chemoradiation therapy
Qunsheng Huang, Huabo Qin, Jian Xiao, Xiaosheng He, Minghao Xie, Xin He, Qiuqiong Yao, Ping Lan, Lei Lian
Gastroenterology Report.2019; 7(4): 283. CrossRef
Histopathological factors predicting response to neoadjuvant therapy in gastric carcinoma
M. L. Sánchez de Molina, C. Díaz del Arco, P. Vorwald, D. García-Olmo, L. Estrada, M. J. Fernández-Aceñero
Clinical and Translational Oncology.2018; 20(2): 253. CrossRef
Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy
Rupert Langer, Karen Becker
Virchows Archiv.2018; 472(2): 175. CrossRef
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08)
Roger von Moos, Dieter Koeberle, Sabina Schacher, Stefanie Hayoz, Ralph C. Winterhalder, Arnaud Roth, György Bodoky, Panagiotis Samaras, Martin D. Berger, Daniel Rauch, Piercarlo Saletti, Ludwig Plasswilm, Daniel Zwahlen, Urs R. Meier, Pu Yan, Paola Izzo,
European Journal of Cancer.2018; 89: 82. CrossRef
A qualitative signature for predicting pathological response to neoadjuvant chemoradiation in locally advanced rectal cancers
You Guo, Weizhong Jiang, Lu Ao, Kai Song, Huxing Chen, Qingzhou Guan, Qiao Gao, Jun Cheng, Huaping Liu, Xianlong Wang, Guoxian Guan, Zheng Guo
Radiotherapy and Oncology.2018; 129(1): 149. CrossRef
Prediction of lateral pelvic lymph node metastasis in patients with locally advanced rectal cancer with preoperative chemoradiotherapy: Focus on MR imaging findings
Min Ju Kim, Bo Yun Hur, Eun Sun Lee, Boram Park, Jungnam Joo, Min Jung Kim, Sung Chan Park, Ji Yeon Baek, Hee Jin Chang, Dae Yong Kim, Jae Hwan Oh, Ju-Seog Lee
PLOS ONE.2018; 13(4): e0195815. CrossRef
Magnetic resonance tumour regression grade and pathological correlates in patients with rectal cancer
J K Jang, J L Lee, S H Park, H J Park, I J Park, J H Kim, S H Choi, J Kim, C S Yu, J C Kim
British Journal of Surgery.2018; 105(12): 1671. CrossRef
Impact of Tumor Regression Grade as a Major Prognostic Factor in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy: A Proposal for a Modified Staging System
Changhoon Song, Joo-Hyun Chung, Sung-Bum Kang, Duck-Woo Kim, Heung-Kwon Oh, Hye Seung Lee, Jin Won Kim, Keun-Wook Lee, Jee Hyun Kim, Jae-Sung Kim
Cancers.2018; 10(9): 319. CrossRef
Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy for Patients with ypN0 Rectal Cancer
Karina Vychnevskaia, Frederic Dumont, Julie Agostini, Catherine Julié, Peggy Dartigues, Thierry Lazure, Valérie Boige, Diane Goéré, Antoine Brouquet, Christophe Penna, Frédérique Peschaud, Stéphane Benoist
Annals of Surgical Oncology.2017; 24(5): 1304. CrossRef
Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer
Delphine Dayde, Ichidai Tanaka, Rekha Jain, Mei Tai, Ayumu Taguchi
International Journal of Molecular Sciences.2017; 18(3): 573. CrossRef
Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy
Luca Reggiani Bonetti, Simona Lionti, Federica Domati, Giuliana Pagliani, Elisabetta Mattioli, Valeria Barresi
Histopathology.2017; 71(3): 393. CrossRef
Applicability of American Joint Committee on Cancer and College of American Pathologists Regression Grading System in Rectal Cancer
Tarkan Jäger, Daniel Neureiter, Romana Urbas, Eckhard Klieser, Wolfgang Hitzl, Klaus Emmanuel, Adam Dinnewitzer
Diseases of the Colon & Rectum.2017; 60(8): 815. CrossRef
Endoscopic assessment of tumor regression after preoperative chemoradiotherapy as a prognostic marker in locally advanced rectal cancer
Dae Kyung Sohn, Kyung Su Han, Byung Chang Kim, Chang Won Hong, Hee Jin Chang, Ji Yeon Baek, Min Ju Kim, Sung Chan Park, Jae Hwan Oh, Dae Yong Kim
Surgical Oncology.2017; 26(4): 453. CrossRef
Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery?
Luca Reggiani Bonetti, Simona Lionti, Federica Domati, Valeria Barresi
World Journal of Gastroenterology.2017; 23(8): 1412. CrossRef
Identification of protein clusters predictive of tumor response in rectal cancer patients receiving neoadjuvant chemo-radiotherapy
Ombretta Repetto, Valli De Re, Antonino De Paoli, Claudio Belluco, Lara Alessandrini, Vincenzo Canzonieri, Renato Cannizzaro
Oncotarget.2017; 8(17): 28328. CrossRef
Discriminating cancer-related and cancer-unrelated chemoradiation-response genes for locally advanced rectal cancers
You Guo, Jun Cheng, Lu Ao, Xiangyu Li, Qingzhou Guan, Juan Zhang, Haidan Yan, Hao Cai, Qiao Gao, Weizhong Jiang, Zheng Guo
Scientific Reports.2016;[Epub] CrossRef
Analysis of long-term outcomes and application of the tumor regression grading system in the therapeutic assessment of resectable limited-disease small cell lung cancer
Shuonan Xu, Jianfei Zhu, Yawei Dou, Wei Tian, Yun Dai, Xianghui Luo, Hongtao Wang
Oncology and Translational Medicine.2016; 2(5): 227. CrossRef

26,091 View
570 Download
93 Web of Science
89 Crossref

A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer: Tak Yun, Heung Tae Kim, Ji-Youn Han, Sung Jin Yoon, Hyae Young Kim, Byung-Ho Nam, Jin Soo Lee; Cancer Res Treat. 2016;48(2):465-472. Published online May 26, 2015; DOI: https://doi.org/10.4143/crt.2015.061

Abstract PDF PubReader ePub

Purpose
Paclitaxel (P) and gemcitabine (G) are clinically synergistic in small cell lung cancer (SCLC). We evaluated the efficacy of PG as a salvage treatment for SCLC patients whose disease progressed after a platinum-containing regimen.
Materials and Methods
Eligibility included histologically confirmed SCLC, one dimensionally measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and progressive disease after platinum-based chemotherapy. Treatment consisted of P (80 mg/m2) and G (1,000 mg/m2) on days 1 and 8 of each cycle of 21 days until disease progression.
Results
Thirty-three patients seen between December 2005 and February 2009 were selected into this study. Thirty patients (91%) had received irinotecan-platinum, and three had received etoposide-platinum. Sixteen patients (49%) had a treatment-free interval of less than 3 months. The overall response rate was 30.3% (29.4% in sensitive relapse and 31.3% in refractory relapse). The median time to progression was 12.0 weeks and median overall survival (OS) 31.0 weeks, with a 1-year OS rate of 30.3%. Toxicities were moderate and manageable with 18.2% grade (G) 4 neutropenia, 24.2% G3 thrombocytopenia, 6.1% G3 sensory neuropathy, and 3% G3 asthenia. One patient developed febrile neutropenia.
Conclusion
Second-line paclitaxel and gemcitabine were well-tolerated and moderately active in SCLC patients previously treated with platinum-based chemotherapy.

Citations

Citations to this article as recorded by

Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway
Shuxin Li, Jianyi Lv, Zhihui Li, Qiuyu Zhang, Jing Lu, Xueyun Huo, Meng Guo, Xin Liu, Changlong Li, Jinghui Wang, Hanping Shi, Li Deng, Zhenwen Chen, Xiaoyan Du
Molecular Cancer.2024;[Epub] CrossRef
Impact of Nab-Paclitaxel Plus PD-1/PD-L1 Inhibitor on Chemorefractory Relapsed Small-Cell Lung Cancer
Fengchun Mu, Bingjie Fan, Haoqian Li, Wenru Qin, Chunni Wang, Bing Zou, Linlin Wang
Future Oncology.2023; 19(19): 1367. CrossRef
Iron oxide nanoparticles induce ferroptosis via the autophagic pathway by synergistic bundling with paclitaxel
Qi Nie, Wenqing Chen, Tianmei Zhang, Shangrong Ye, Zhongyu Ren, Peng Zhang, Jian Wen
Molecular Medicine Reports.2023;[Epub] CrossRef
Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy
Zhonglin Hao, Janeesh Sekkath Veedu
Clinical Lung Cancer.2022; 23(1): 14. CrossRef
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis
Jan A. Stratmann, Radha Timalsina, Akin Atmaca, Vivian Rosery, Nikolaj Frost, Jürgen Alt, Cornelius F. Waller, Niels Reinmuth, Gernot Rohde, Felix C. Saalfeld, Aaron Becker von Rose, Fabian Acker, Lukas Aspacher, Miriam Möller, Martin Sebastian
Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef
Functionalized FcRn-targeted nanosystems for oral drug delivery: A new approach to colorectal cancer treatment
Fatima Hameedat, Nuria A. Pizarroso, Natália Teixeira, Soraia Pinto, Bruno Sarmento
European Journal of Pharmaceutical Sciences.2022; 176: 106259. CrossRef
Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data
Chengcheng Gong, Yizhao Xie, Yannan Zhao, Yi Li, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Xichun Hu, Biyun Wang
Therapeutic Advances in Drug Safety.2022;[Epub] CrossRef
Impact of Nab-Paclitaxel Plus PD-1/PD-L1 Inhibitor Versus Traditional Chemotherapy for Retreatment Small Cell Lung Cancer Patients
Fengchun Mu, Bingjie Fan, Wenru Qin, Shijiang Wang, Bing Zou, Linlin Wang
SSRN Electronic Journal .2022;[Epub] CrossRef
FcRn expression in cancer: Mechanistic basis and therapeutic opportunities
Imke Rudnik-Jansen, Kenneth A. Howard
Journal of Controlled Release.2021; 337: 248. CrossRef
Nanoparticle Albumin Bound Paclitaxel in the Third-Line Treatment of Recurrent Small Cell Lung Cancer in Real-World Practice: A Single Center Experience
Yuchao Wang, Li Li, Chunhua Xu
Technology in Cancer Research & Treatment.2021;[Epub] CrossRef
Combination therapy with carboplatin and paclitaxel for small cell lung cancer
Atsuto Mouri, Ou Yamaguchi, Sachiko Miyauchi, Ayako Shiono, Harue Utsugi, Fuyumi Nishihara, Yoshitake Murayama, Hiroshi Kagamu, Kunihiko Kobayashi
Respiratory Investigation.2019; 57(1): 34. CrossRef
Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens
Yuji Takei, Yoshifumi Takahashi, Shizuo Machida, Akiyo Taneichi, Suzuyo Takahashi, Tomomi Nagashima, Hiroyuki Morisawa, Yasushi Saga, Shigeki Matsubara, Hiroyuki Fujiwara
Journal of Obstetrics and Gynaecology Research.2017; 43(2): 358. CrossRef
Second-line treatments of small-cell lung cancers
Nathalie Baize, Isabelle Monnet, Laurent Greillier, Gilles Quere, Mallorie Kerjouan, Henri Janicot, Alain Vergnenegre, Jean Bernard Auliac, Christos Chouaid
Expert Review of Anticancer Therapy.2017; 17(11): 1033. CrossRef

12,586 View
126 Download
12 Web of Science
13 Crossref

Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome: Siew Kuan Lim, Moo Hyun Lee, In Hae Park, Ji Young You, Byung-Ho Nam, Byeong Nam Kim, Jungsil Ro, Keun Seok Lee, So-Youn Jung, Young Mee Kwon, Eun Sook Lee; Cancer Res Treat. 2016;48(1):133-141. Published online April 7, 2015; DOI: https://doi.org/10.4143/crt.2014.262

Abstract PDF PubReader ePub

Purpose
The aim of this study was to examine molecular subtype conversions in patients who underwent neoadjuvant chemotherapy (NAC) and analyze their clinical implications.
Materials and Methods
We included consecutive breast cancer patients who received NAC at the National Cancer Center, Korea, between August 2002 and June 2011, and had available data on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) receptor status prior to NAC. Molecular subtypes, hormone receptor (HR) status, and ER and PR Allred scores before and after NAC were compared, and the long-term outcomes were analyzed.
Results
Of 322 patients, 32 (9.9%) achieved a pathologic complete response after NAC. HR+/HER2– tumors tended to convert into triple negative (TN) tumors (10.3%), whereas 34.6% of TN tumors gained HR positivity to become HR+/HER2– tumors. Clinical outcomes of molecular subtype conversion groups were compared against patients who remained as HR+/HER2– throughout. The HR+/HER2– to TN group had significantly poorer recurrencefree survival (RFS) (hazard ratio, 3.54; 95% confidence interval [CI], 1.60 to 7.85) and overall survival (OS) (hazard ratio, 3.73; 95% CI, 1.34 to 10.38). Patients who remained TN throughout had the worst outcomes (for RFS: hazard ratio, 3.70; 95% CI, 1.86 to 7.36; for OS: hazard ratio, 5.85; 95% CI, 2.53 to 13.51), while those who converted from TN to HR+/HER2– showed improved comparable survival outcomes.
Conclusion
Molecular subtypes of breast cancers changed frequently after NAC, resulting in different tumor prognostication. Tumor subtyping should be repeated after NAC in patients with breast cancer.

Citations

Citations to this article as recorded by

Molecular Classification of Breast Cancer Using Weakly Supervised Learning
Wooyoung Jang, Jonghyun Lee, Kyong Hwa Park, Aeree Kim, Sung Hak Lee, Sangjeong Ahn
Cancer Research and Treatment.2025; 57(1): 116. CrossRef
Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients
Mijia Wang, Zhendong Wei, Jixia Kong, Haidong Zhao
Diagnostic Pathology.2024;[Epub] CrossRef
Texture analysis using non-contrast MRI to predict estrogen receptor status in breast cancer lesions: Is it feasible?
F.A. Shokeir, A.H. Elmokadem, N. Soliman, A. Khater, D. Bayoumi
Clinical Radiology.2024; 79(7): e892. CrossRef
Case report: Heterogeneity in the primary lesions of invasive micropapillary breast carcinoma
Yang Fu, Junwei Cui, Jinming Zhou, Fang Li, Jinsong He, Zijian Yang
Current Problems in Cancer: Case Reports.2024; 16: 100321. CrossRef
Breast Panel Biomarker Changes After Neoadjuvant Chemotherapy in Breast Cancer
Kris Raychelle Godoy, Manuelito Madrid
PJP.2024; 9(1): 17. CrossRef
Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy
Sudheer Vemuru, Jin Huang, Kathryn Colborn, YooJin Yoon, Victoria Huynh, Laura Leonard, Gretchen Ahrendt, Nicole Christian, Anosheh Afghahi, Lauren McLemore, Sharon Sams, Sarah Tevis
Breast Cancer Research and Treatment.2023; 200(2): 247. CrossRef
Inflammasomes in breast cancer: the ignition spark of progression and resistance?
Sawsan Elgohary, Hend M. El Tayebi
Expert Reviews in Molecular Medicine.2023;[Epub] CrossRef
Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature
Jan Paredes Mogica, Haiming Tang, Yuanxin Liang, Minghao Zhong, Pei Hui, Malini Harigopal, Uma Krishnamurti, Neal A. Fischbach, Haiying Zhan
The Breast.2023; 72: 103586. CrossRef
Research Progress and Future Prospect of HER-2 Low Expression Breast Cancer
·米尔扎合买提买吐鲁佰
Advances in Clinical Medicine.2023; 13(10): 16593. CrossRef
Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement
Elena Guerini-Rocco, Gerardo Botti, Maria Pia Foschini, Caterina Marchiò, Mauro Giuseppe Mastropasqua, Giuseppe Perrone, Elena Roz, Alfredo Santinelli, Isabella Sassi, Viviana Galimberti, Luca Gianni, Giuseppe Viale
Tumori Journal.2022; 108(3): 196. CrossRef
HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review
Luo Wang, Qi Jiang, Meng-Ye He, Peng Shen
World Journal of Clinical Cases.2022; 10(1): 260. CrossRef
Alterations in Breast Cancer Biomarkers Following Neoadjuvant Therapy
Srivarshini Cherukupalli Mohan, Sarah Walcott-Sapp, Minna K. Lee, Marissa K. Srour, Sungjin Kim, Farin F. Amersi, Armando E. Giuliano, Alice P. Chung
Annals of Surgical Oncology.2021; 28(11): 5907. CrossRef
Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience
Saverio Coiro, Elisa Gasparini, Giuseppe Falco, Giacomo Santandrea, Moira Foroni, Giulia Besutti, Valentina Iotti, Roberto Di Cicilia, Monica Foroni, Simone Mele, Guglielmo Ferrari, Giancarlo Bisagni, Moira Ragazzi
Diagnostics.2021; 11(12): 2249. CrossRef
Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy—a survey of pathologists in academic institutions across the United States
Sonali Lanjewar, Priyanka Patil, Susan Fineberg
Modern Pathology.2020; 33(1): 91. CrossRef
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
Soomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park
Journal of Pathology and Translational Medicine.2020; 54(1): 34. CrossRef
Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP‐1 and HER2 expression and converted MCF7 breast cancer subtype
Noura Al‐Zeheimi, Sirin A. Adham
British Journal of Pharmacology.2020; 177(9): 2024. CrossRef
Bilateral Triple Negative Invasive Ductal Breast Carcinoma in a BRCA1 Mutation Carrier with Discrepant Pathologic Response to Neoadjuvant Chemotherapy
Gi Won Shin, Young Mi Park, Tae Hyun Kim, Anbok Lee, Ha Young Park, Hye Kyoung Yoon, Young Jin Heo, Jin Wook Baek, Yoo Jin Lee
Journal of the Korean Society of Radiology.2020; 81(2): 428. CrossRef
A Six-Epithelial–Mesenchymal Transition Gene Signature May Predict Metastasis of Triple-Negative Breast Cancer

Li Yuan Wei, Xiao Jun Zhang, Li Wang, Li Na Hu, Xu Dong Zhang, Li Li, Jin Nan Gao
OncoTargets and Therapy.2020; Volume 13: 6497. CrossRef
Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes
Haoyu Wang, Jiejie Yao, Ying Zhu, Weiwei Zhan, Xiaosong Chen, Kunwei Shen
Cancer Medicine.2020; 9(17): 6173. CrossRef
Effect of neoadjuvant therapy on breast cancer biomarker profile
Laura Rey-Vargas, Juan Carlos Mejía-Henao, María Carolina Sanabria-Salas, Silvia J. Serrano-Gomez
BMC Cancer.2020;[Epub] CrossRef
Surrogate Molecular Classification of Invasive Breast Carcinoma: A Comparison Between Core Needle Biopsy and Surgical Excision, With and Without Neoadjuvant Therapy
Andrea Ambrosini-Spaltro, Elena Zunarelli, Stefania Bettelli, Massimo Lupi, Giuditta Bernardelli, Marina Milani, Guido Ficarra
Applied Immunohistochemistry & Molecular Morphology.2020; 28(7): 551. CrossRef
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
Emma Zattarin, Rita Leporati, Francesca Ligorio, Riccardo Lobefaro, Andrea Vingiani, Giancarlo Pruneri, Claudio Vernieri
Cells.2020; 9(12): 2644. CrossRef
Prediction of breast cancer molecular subtypes using radiomics signatures of synthetic mammography from digital breast tomosynthesis
Jinwoo Son, Si Eun Lee, Eun-Kyung Kim, Sungwon Kim
Scientific Reports.2020;[Epub] CrossRef
Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis
Chao Li, Hongwei Fan, Qian Xiang, Ling Xu, Zhuo Zhang, Qianxin Liu, Tongtong Zhang, Jinjie Ling, Ying Zhou, Xia Zhao, Yimin Cui
Breast Cancer Research and Treatment.2019; 178(3): 497. CrossRef
Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy
Xinyan Li, Mozhi Wang, Mengshen Wang, Xueting Yu, Jingyi Guo, Tie Sun, Litong Yao, Qiang Zhang, Yingying Xu
Journal of Breast Cancer.2019; 22(4): 497. CrossRef
Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Jason J. Zoeller, Aleksandr Vagodny, Krishan Taneja, Benjamin Y. Tan, Neil O'Brien, Dennis J. Slamon, Deepak Sampath, Joel D. Leverson, Roderick T. Bronson, Deborah A. Dillon, Joan S. Brugge
Molecular Cancer Therapeutics.2019; 18(6): 1115. CrossRef
Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer
Soomin Ahn, Hyun Jeong Kim, Milim Kim, Yul Ri Chung, Eunyoung Kang, Eun-Kyu Kim, Se Hyun Kim, Yu Jung Kim, Jee Hyun Kim, In Ah Kim, So Yeon Park
Cancer Research and Treatment.2018; 50(4): 1418. CrossRef
Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How?
Lucy M. De La Cruz, Michael O. Harhay, Paul Zhang, Stacy Ugras
Annals of Surgical Oncology.2018; 25(12): 3535. CrossRef
Modern therapies and iatrogenic changes in breast pathology
Elena Provenzano, Sarah E Pinder
Histopathology.2017; 70(1): 40. CrossRef
Biomarkers of residual disease after neoadjuvant therapy for breast cancer
Frederique Penault-Llorca, Nina Radosevic-Robin
Nature Reviews Clinical Oncology.2016; 13(8): 487. CrossRef
CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype
Tuan Zea Tan, He Yang, Jieru Ye, Jeffrey Low, Mahesh Choolani, David Shao Peng Tan, Jean-Paul Thiery, Ruby Yun-Ju Huang
Oncotarget.2015; 6(41): 43843. CrossRef

15,381 View
200 Download
33 Web of Science
31 Crossref

Robotic Versus Laparoscopic Surgery for Rectal Cancer after Preoperative Chemoradiotherapy: Case-Matched Study of Short-Term Outcomes: Yong Sok Kim, Min Jung Kim, Sung Chan Park, Dae Kyung Sohn, Dae Yong Kim, Hee Jin Chang, Byung-Ho Nam, Jae Hwan Oh; Cancer Res Treat. 2016;48(1):225-231. Published online March 11, 2015; DOI: https://doi.org/10.4143/crt.2014.365

Abstract PDF PubReader ePub

Purpose
Robotic surgery is expected to have advantages over laparoscopic surgery; however, there are limited data regarding the feasibility of robotic surgery for rectal cancer after preoperative chemoradiotherapy (CRT). Therefore, we evaluated the short-term outcomes of robotic surgery for rectal cancer. Materials and Methods Thirty-three patients with cT3N0-2 rectal cancer after preoperative CRT who underwent robotic low anterior resection (R-LAR) between March 2010 and January 2012 were matched with 66 patients undergoing laparoscopic low anterior resection (L-LAR). Perioperative clinical outcomes and pathological data were compared between the two groups.
Results
Patient characteristics did not differ significantly different between groups. The mean operation time was 441 minutes (R-LAR) versus 277 minutes (L-LAR; p < 0.001). The open conversion rate was 6.1% in the R-LAR group and 0% in the L-LAR group (p=0.11). There were no significant differences in the time to flatus passage, length of hospital stay, and postoperative morbidity. In pathological review, the mean number of harvested lymph nodes was 22.3 in R-LAR and 21.6 in L-LAR (p=0.82). Involvement of circumferential resection margin was positive in 16.1% and 6.7%, respectively (p=0.42). Total mesorectal excision (TME) quality was complete in 97.0% in R-LAR and 91.0% in L-LAR (p=0.41). Conclusion In our study, short-term outcomes of robotic surgery for rectal cancer after CRT were similar to those of laparoscopic surgery in respect to bowel function recovery, morbidity, and TME quality. Well-designed clinical trials are needed to evaluate the functional results and longterm outcomes of robotic surgery for rectal cancer.

Citations

Citations to this article as recorded by

The role of robotic-assisted surgery in the management of rectal cancer: a systematic review and meta-analysis
Chenxiong Zhang, Hao Tan, Han Xu, Jiaming Ding
International Journal of Surgery.2024; 110(10): 6282. CrossRef
Robotic-Assisted versus Laparoscopic Surgery for Rectal Cancer: An Analysis of Clinical and Financial Outcomes from a Tertiary Referral Center
Jasper Max Gebhardt, Neno Werner, Andrea Stroux, Frank Förster, Ioannis Pozios, Claudia Seifarth, Christian Schineis, Benjamin Weixler, Katharina Beyer, Johannes Christian Lauscher
Journal of Clinical Medicine.2024; 13(6): 1795. CrossRef
Association of Surgical Approaches and Outcomes in Total Mesorectal Excision and Margin Status for Rectal Cancer
Muhammad Bilal Mirza, Adriana C. Gamboa, Rebecca Irlmeier, Benjamin Hopkins, Scott E. Regenbogen, Katherine A. Hrebinko, Jennifer Holder-Murray, Jason T. Wiseman, Aslam Ejaz, Paul E. Wise, Fei Ye, Kamran Idrees, Alexander T. Hawkins, Glen C. Balch, Aimal
Journal of Surgical Research.2024; 300: 494. CrossRef
Rapidez y Precisión en la Comunicación en Tiempo Real entre el Laboratorio Clínico y el Médico durante la Cirugía Robótica
Alfredo Ibarra-Sánchez, Claudia Soto-Félix, Leticia Cano-Barraza, Delia Barraza-Sámano
Estudios y Perspectivas Revista Científica y Académica .2024; 4(4): 1463. CrossRef
Surgical outcomes of robotic, laparoscopic, and open low anterior resection after preoperative chemoradiotherapy for patients with advanced lower rectal cancer
Sukchol Lim, Yuzo Nagai, Hiroaki Nozawa, Kazushige Kawai, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Tsuyoshi Ozawa, Shinya Abe, Hiroyuki Anzai, Hirofumi Sonoda, Soichiro Ishihara
Surgery Today.2023; 53(1): 109. CrossRef
Operative and oncological outcomes after robotic rectal resection compared with laparoscopy: a systematic review and meta‐analysis
Julie Flynn, Jose T. Larach, Joseph C. H. Kong, Jessica Rahme, Peadar S. Waters, Satish K. Warrier, Alexander Heriot
ANZ Journal of Surgery.2023; 93(3): 510. CrossRef
Comparison of Operative Time Between Robotic and Laparoscopic Low Anterior Resection for Rectal Cancer:A Systematic Review and Meta-Analysis
Zhen Chen, Hua Yu, Huaping Wu, Pingxi Wang, Fanwei Zeng
Surgical Innovation.2023; 30(3): 390. CrossRef
Robotic Rectal Resection for Rectal Cancer in Elderly Patients: A Systematic Review and Meta-Analysis
Rossella Reddavid, Silvia Sofia, Lucia Puca, Jacopo Moro, Simona Ceraolo, Rosa Jimenez-Rodriguez, Maurizio Degiuli
Journal of Clinical Medicine.2023; 12(16): 5331. CrossRef
Short-term and long-term efficacy in robot-assisted treatment for mid and low rectal cancer: a systematic review and meta-analysis
Huiming Wu, Renkai Guo, Huiyu Li
International Journal of Colorectal Disease.2023;[Epub] CrossRef
Robotic versus laparoscopic surgery for rectal cancer after neoadjuvant chemoradiotherapy: A propensity-score matching analysis
Tzu-Chun Chen, Jin-Tung Liang
Journal of the Formosan Medical Association.2022; 121(8): 1532. CrossRef
Short‐term outcomes of robotic‐assisted surgery following neoadjuvant chemotherapy for lower rectal cancer
Hajime Morohashi, Yoshiyuki Sakamoto, Takuya Miura, Daichi Ichinohe, Shunsuke Kubota, Keisuke Yamazaki, Aika Ichisawa, Yuto Mitsuhashi, Taiichi Wakiya, Kenichi Hakamada
Asian Journal of Endoscopic Surgery.2022; 15(3): 577. CrossRef
Robotic versus Laparoscopic Low Anterior Resection for Rectal Cancer
Aba Khaled M. Farid Uddin
World Journal of Colorectal Surgery.2022; 11(3): 47. CrossRef
Oncological outcomes of robotic-assisted total mesorectal excision after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer
Po-Jung Chen, Wei-Chih Su, Tsung-Kun Chang, Yen-Cheng Chen, Ching-Chun Li, Tzu-Chieh Yin, Hsiang-Lin Tsai, Cheng-Jen Ma, Ching-Wen Huang, Jaw-Yuan Wang
Asian Journal of Surgery.2021; 44(7): 957. CrossRef
Difference in surgical outcomes of rectal cancer by study design: meta-analyses of randomized clinical trials, case-matched studies, and cohort studies
N Hoshino, T Sakamoto, K Hida, Y Takahashi, H Okada, K Obama, T Nakayama
BJS Open.2021;[Epub] CrossRef
Postoperative complications observed with robotic versus laparoscopic surgery for the treatment of rectal cancer
Chengkui Liu, Xiaoqing Li, Qingfeng Wang
Medicine.2021; 100(36): e27158. CrossRef
Robotic and robotic-assisted vs laparoscopic rectal cancer surgery: A meta-analysis of short-term and long-term results
Guojun Tong, Guiyang Zhang, Zhaozheng Zheng
Asian Journal of Surgery.2021;[Epub] CrossRef
Robotic-Assisted vs. Standard Laparoscopic Surgery for Rectal Cancer Resection: A Systematic Review and Meta-Analysis of 19,731 Patients
Kamil Safiejko, Radoslaw Tarkowski, Maciej Koselak, Marcin Juchimiuk, Aleksander Tarasik, Michal Pruc, Jacek Smereka, Lukasz Szarpak
Cancers.2021; 14(1): 180. CrossRef
Robotic versus Laparoscopic Colorectal Surgeries
Anil Heroor, Aysha Khan, Kashish Jain, Akshay Patil, Hitesh Rajendra Singhavi
Indian Journal of Colo-Rectal Surgery.2021; 4(1): 12. CrossRef
Feasibility of robot-assisted surgery in elderly patients with rectal cancer
Wei-Chih Su, Ching-Wen Huang, Cheng-Jen Ma, Po-Jung Chen, Hsiang-Lin Tsai, Tsung-Kun Chang, Yen-Cheng Chen, Ching-Chun Li, Yung-Sung Yeh, Jaw-Yuan Wang
Journal of Minimal Access Surgery.2021; 17(2): 165. CrossRef
Robotic surgery for colorectal disease: review of current port placement and future perspectives
Jong Lyul Lee, Hassan A. Alsaleem, Jin Cheon Kim
Annals of Surgical Treatment and Research.2020; 98(1): 31. CrossRef
Comparison of clinical efficacy between robotic-laparoscopic excision and traditional laparoscopy for rectal cancer
Zhen Chen, Zhuo Li Zhu, Pingxi Wang, Fanwei Zeng
Medicine.2020; 99(27): e20704. CrossRef
Oncological Outcomes of Robotic-Assisted Surgery With High Dissection and Selective Ligation Technique for Sigmoid Colon and Rectal Cancer
Tzu-Chieh Yin, Wei-Chih Su, Po-Jung Chen, Tsung-Kun Chang, Yen-Cheng Chen, Ching-Chun Li, Yi-Chien Hsieh, Hsiang-Lin Tsai, Ching-Wen Huang, Jaw-Yuan Wang
Frontiers in Oncology.2020;[Epub] CrossRef
Robotic Total Mesorectal Excision for Rectal Cancer: Current Evidences and Future Perspectives
Je-Ho Jang, Chang-Nam Kim
Annals of Coloproctology.2020; 36(5): 293. CrossRef
Systematic review analysis of robotic and transanal approaches in TME surgery- A systematic review of the current literature in regard to challenges in rectal cancer surgery
Julia K. Grass, Daniel R. Perez, Jakob R. Izbicki, Matthias Reeh
European Journal of Surgical Oncology.2019; 45(4): 498. CrossRef
Robotic Versus Conventional Laparoscopic Surgery for Colorectal Cancer: A Systematic Review and Meta‐Analysis with Trial Sequential Analysis
Ka Ting Ng, Azlan Kok Vui Tsia, Vanessa Yu Ling Chong
World Journal of Surgery.2019; 43(4): 1146. CrossRef
Robotic versus conventional laparoscopic surgery for rectal cancer: systematic review and meta-analysis
Xi-Yu Sun, Lai Xu, Jun-Yang Lu, Guan-Nan Zhang
Minimally Invasive Therapy & Allied Technologies.2019; 28(3): 135. CrossRef
Systemic review and network meta‐analysis comparing minimal surgical techniques for rectal cancer: quality of total mesorectum excision, pathological, surgical, and oncological outcomes
Emanuele Rausa, Federica Bianco, Michael E. Kelly, Alberto Aiolfi, Fausto Petrelli, Gianluca Bonitta, Giovanni Sgroi
Journal of Surgical Oncology.2019; 119(7): 987. CrossRef
TME for rectal cancer: consecutive 70 patients treated with laparoscopic and robotic technique—cumulative experience in a single centre
J. L. Mégevand, E. Lillo, M. Amboldi, L. Lenisa, A. Ambrosi, A. Rusconi
Updates in Surgery.2019; 71(2): 331. CrossRef
Completeness of total mesorectum excision of laparoscopic versus robotic surgery: a review with a meta-analysis
Marco Milone, Michele Manigrasso, Nunzio Velotti, Stefania Torino, Antonietta Vozza, Giovanni Sarnelli, Giovanni Aprea, Francesco Maione, Nicola Gennarelli, Mario Musella, Giovanni Domenico De Palma
International Journal of Colorectal Disease.2019; 34(6): 983. CrossRef
Immediate results of robotic-assisted operations in colorectal surgery
Yu. M. Stojko, A. V. Maksimenkov, A. L. Levchuk, D. A. Kolozyan
Endoskopicheskaya khirurgiya.2019; 25(2): 5. CrossRef
Short-Term Outcomes of Robotic versus Laparoscopic Total Mesorectal Excision for Rectal Cancer: A Cohort Study
Wen-Han Liu, Pei-Jing Yan, Dong-Ping Hu, Peng-Hui Jin, Yao-Chun Lv, Rong Liu, Xiong-Fei Yang, Ke-Hu Yang, Tian-Kang Guo
The American Surgeon™.2019; 85(3): 294. CrossRef
Operative time and length of stay is similar between robotic assisted and laparoscopic colon and rectal resections
Heather R. Nolan, Betsy E. Smith, Michael D. Honaker
Journal of Robotic Surgery.2018; 12(4): 659. CrossRef
Does robotic rectal cancer surgery improve the results of experienced laparoscopic surgeons? An observational single institution study comparing 168 robotic assisted with 184 laparoscopic rectal resections
Rogier M. P. H. Crolla, Paul G. Mulder, George P. van der Schelling
Surgical Endoscopy.2018; 32(11): 4562. CrossRef
Robotic total meso-rectal excision for rectal cancer: A systematic review following the publication of the ROLARR trial
Katie Jones, Mohamed G Qassem, Parv Sains, Mirza K Baig, Muhammad S Sajid
World Journal of Gastrointestinal Oncology.2018; 10(11): 449. CrossRef
Recent surgical advances in colorectal cancer excision: toward optimal outcomes
Cihangir Akyol, Mehmet Ayhan Kuzu
Colorectal Cancer.2017; 5(4): 147. CrossRef
The safety and effectiveness of robot-assisted versus laparoscopic TME in patients with rectal cancer
Xiaofei Li, Tao Wang, Liang Yao, Lidong Hu, Penghui Jin, Tiankang Guo, Kehu Yang
Medicine.2017; 96(29): e7585. CrossRef
Robotic-assisted total mesorectal excision with the single-docking technique for patients with rectal cancer
Ching-Wen Huang, Hsiang-Lin Tsai, Yung-Sung Yeh, Wei-Chih Su, Ming-Yii Huang, Chun-Ming Huang, Yu-Tang Chang, Jaw-Yuan Wang
BMC Surgery.2017;[Epub] CrossRef
Robotic Surgery for Rectal Cancer: An Update in 2015
Jung Myun Kwak, Seon Hahn Kim
Cancer Research and Treatment.2016; 48(2): 427. CrossRef
La chirurgie robotique dans le cancer du rectum
J. Coget, P. E. Colombo, A. Mourregot, D. Traoré, P. Rouanet
Oncologie.2016; 18(5): 305. CrossRef
Robot-assisted versus laparoscopic-assisted surgery for colorectal cancer: a meta-analysis
Xuan Zhang, ZhengQiang Wei, MengJun Bie, XuDong Peng, Cheng Chen
Surgical Endoscopy.2016; 30(12): 5601. CrossRef
Robotics in Colorectal Surgery
Allison Weaver, Scott Steele
F1000Research.2016; 5: 2373. CrossRef

12,916 View
134 Download
40 Web of Science
41 Crossref

First
Prev
Page of 1
Next
Last

Search